Asset Details
Do you wish to reserve the book?
Serum S100A12 levels are associated with the presence and severity of obstructive sleep apnea syndrome in male patients
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Serum S100A12 levels are associated with the presence and severity of obstructive sleep apnea syndrome in male patients
Do you wish to request the book?
Serum S100A12 levels are associated with the presence and severity of obstructive sleep apnea syndrome in male patients
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Serum S100A12 levels are associated with the presence and severity of obstructive sleep apnea syndrome in male patients
2014
Overview
Purpose
Inflammation plays a critical role in the pathogenesis of obstructive sleep apnea syndrome (OSAS). S100A12 is a newly identified inflammatory biomarker. This study aims to investigate whether serum S100A12 levels are associated with the presence and severity of OSAS in male patients.
Methods
A total of 126 male patients with OSAS and 74 controls were enrolled in this study. The presence and severity of OSAS was assessed by apnea–hypopnea index (AHI). Serum S100A12 levels were detected by enzyme-linked immunosorbent assay.
Results
Serum S100A12 levels were significantly higher in the OSAS group than in the control group (132.17 (range 101.86 to 174.49) ng/ml vs. 78.40 (range 58.35 to 129.44) ng/ml,
P
< 0.01). Multivariate logistic regression demonstrated that S100A12 was the only significant and independent predictor of OSAS (odds ratio 1.012, 95 % confidence interval 1.006 to 1.017;
P
< 0.01). Serum S100A12 levels elevated with the increase in the severity of OSAS (S100A12 levels of 106.04 (range 83.92 to 135.13) ng/ml in mild OSAS group, 133.51 (range 109.64 to 208.95) ng/ml in moderate OSAS group, and 173.04 (range 131.88 to 275.77) ng/ml in severe OSAS group;
P
< 0.001). Serum S100A12 levels were independently correlated with AHI scores (
r
= 0.324,
P
< 0.001)
Conclusions
Serum S100A12 levels were independently associated with the presence and severity of OSAS. These findings suggest that serum S100A12 level could be a potential biomarker for reflecting the presence and severity of OSAS.
Publisher
Springer Berlin Heidelberg,Springer,Springer Nature B.V
Subject
/ Aged
/ Biological and medical sciences
/ Enzyme-Linked Immunosorbent Assay
/ Fundamental and applied biological sciences. Psychology
/ Groups
/ Humans
/ Inflammation Mediators - blood
/ Male
/ Males
/ Medicine
/ Nervous system (semeiology, syndromes)
/ Patients
/ Pneumology/Respiratory System
/ Respiratory system : syndromes and miscellaneous diseases
/ Serum
/ Severity
/ Sleep
/ Sleep Apnea, Obstructive - blood
/ Sleep Apnea, Obstructive - classification
